insights_auto
Kwa nini 2X1 imeongezeka kwa 2.86%?
Fahamu zaidichevron_right
2X1:ETR
Abivax SA
€ 79.00
arrow_upward
+2.86%(+2.20) Siku 1
9 Okt, 17:35:37 GMT +2 · EUR
search
Alama zote
| Alama | Bei | Tofauti | Tofauti ya asilimia |
|---|
insights_autoInatayarisha maarifa maarufu ya 2X1...
Fungua
€ 78.95
Juu
€ 80.40
Chini
€ 78.95
Mtaji wa soko
6.81B
Wastani wa kiasi cha mauzo
elfu 1.81
Kiasi cha mauzo ya hisa
0.00
Juu kwa wiki 52
€ 137.40
Chini kwa wiki 52
€ 60.85
EPS
-€ 5.20
Idadi ya wafanyakazi
98
Fungua
€ 78.95
Juu
€ 80.40
Chini
€ 78.95
Mtaji wa soko
6.81B
Wastani wa kiasi cha mauzo
elfu 1.81
Kiasi cha mauzo ya hisa
0.00
Juu kwa wiki 52
€ 137.40
Chini kwa wiki 52
€ 60.85
EPS
-€ 5.20
Idadi ya wafanyakazi
98
Habari
Kutoka kwenye vyanzo vya wavuti na washirika wa habari
TradingView
·
siku 2 zilizopita
Abivax SA Stock 12‑Month Price Target Cut to $159.06, Implies 79% Upside
Wasifu
Abivax SA is a clinical stage biotechnology company focused on developing innovative treatments that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases.
Abivax has a program in clinical development with its lead drug candidate, obefazimod, to treat ulcerative colitis. Another program in Crohn’s disease is also in preparation and other potential inflammatory indications are being evaluated.
The company’s headquarters are based in Paris, France with a US office in Waltham, Massachusetts. Abivax’s Research and development work is conducted at its research center based in Montpellier, France. Wikipedia
Kuhusu Abivax SA
Afisa Mkuu Mtendaji (CEO)Marc de Garidel | Hartmut J. Ehrlich
Wafanyakazi98
Lilianzishwa4 Des 2013
Makao makuu-
Sekta-
Tovutiabivax.com